MedTrace Logo

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

NCT02513342 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2015-07-31

No results posted yet for this study

Summary

Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.

Conditions

  • Advanced Lung Squamous Carcinoma

Interventions

BIOLOGICAL

Endostar

Endostar 30mg continuous intravenous injection pump,d1-d7；

DRUG

Docetaxel

d4 Docetaxel，75（mg/m2），iv；

DRUG

Cisplatin

d4，cisplatin，75（mg/m2），iv；

Sponsors & Collaborators

  • Nanjing NingQi Medicine Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-10-31
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02513342 on ClinicalTrials.gov